Drug Development Pipeline

At FAST, it’s our job to push forward all promising Angelman syndrome (AS) programs, and to ensure that the community has a birds-eye view of the entire landscape. Many of these programs have been, or still are, funded by FAST, but this chart also includes those that aren’t (but are disclosed). The progress made is truly promising.